Investors focused on the Medical space have likely heard of DexCom (DXCM Quick QuoteDXCM - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

DexCom is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DXCM is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for DXCM's full-year earnings has moved 311.94% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the most recent data, DXCM has returned 19.15% so far this year. At the same time, Medical stocks have gained an average of 1.77%. This means that DexCom is outperforming the sector as a whole this year.

To break things down more, DXCM belongs to the Medical - Instruments industry, a group that includes 90 individual companies and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have gained 3.59% this year, meaning that DXCM is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to DXCM as it looks to continue its solid performance.